• Hedgepath Pharmaceuticals Inc., (HPPI) of Tampa, Fla., said it signed an exclusive supply and license deal with Mayne Pharma International Pty. Ltd., a subsidiary of Melbourne, Australia-based Mayne Pharma Group Ltd., whereby HPPI will pursue clinical development of Mayne’s formulation of itraconazole, known as Suba-Itraconazole, for the treatment of a variety of cancers, with a focus on seeking regulatory approvals and marketing in the U.S.